Table 3 Multivariate analysis for OS, LFFS, DMFS

OS

 Age (>51 vs. ≦51)

0.77 (0.440–1.342)

0.354

 Gender (male vs. female)

4.11 (0.942–17.92)

0.060

 ECE (negative vs. positive)

0.55 (0.257–1.163)

0.117

 Margin (negative vs. positive)

0.52 (0.295–0.916)

0.024

 LNR (≧0.1 vs. < 0.1)

2.92 (1.367–6.242)

0.006

 Absolute number of lymph nodes metastases (1 vs. ≧2)

1.02 (0.661–1.575)

0.928

 Stage (III + IV vs I + II)

1.99 (0.744–5.319)

0.170

 Primary (other primary site vs. oral cavity)

0.59 (0.303–1.160)

0.127

LFFS

 Age (>51 vs. ≦51)

0.34 (0.156–0.729)

0.006

 Gender (male vs. female)

6.10 (0.806–46.14)

0.080

 ECE (negative vs. positive)

0.39 (0.145–1.040)

0.060

 Margin (negative vs. positive)

0.81 (0.358–1.837)

0.615

 LNR (≧0.1 vs. < 0.1)

4.12 (1.604–10.59)

0.003

 Absolute number of lymph nodes metastases (1 vs. ≧2)

1.15 (0.674–1.967)

0.606

 Stage (III + IV vs I + II)

2.09 (0.576–7.567)

0.263

 Primary (other primary site vs. oral cavity)

0.33 (0.112–0.957)

0.041

DMFS

 Age (>51 vs. ≦51)

0.34 (0.132–0.865)

0.024

 Gender (male vs. female)

2.80 (0.360–22.14)

0.323

 ECE (negative vs. positive)

0.68 (0.225–2.057)

0.495

 Margin (negative vs. positive)

2.37 (0.682–8.256)

0.175

 LNR (≧0.1 vs. < 0.1)

3.10 (0.957–10.09)

0.059

 Absolute number of lymph nodes metastases (1 vs. ≧2)

0.85 (0.444–1.635)

0.630

 Stage (III + IV vs I + II)

6.90 (0.176–41.03)

0.199

 Primary (other primary site vs. oral cavity)

0.74 (0.238–2.270)

0.592